Cargando…

World hepatitis day in Burkina Faso, 2017: seroprevalence and vaccination against hepatitis B virus to achieve the 2030 elimination goal

BACKGROUND: Burkina Faso is a high endemicity country for HBV infection. However, there are few data on vaccine coverage against HBV. The aim of this study was to contribute to the improvement of HBV vaccine coverage in Ouagadougou through HBV screening. METHODS: Awareness campaigns and voluntary he...

Descripción completa

Detalles Bibliográficos
Autores principales: Diarra, Birama, Yonli, Albert Theophane, Ouattara, Abdoul Karim, Zohoncon, Theodora Mahoukèdè, Traore, Lassina, Nadembega, Christelle, Obiri-Yeboah, Dorcas, Yara, Justine, Pietra, Virginio, Ouedraogo, Paul, Bougouma, Alain, Sanogo, Rokia, Simpore, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080359/
https://www.ncbi.nlm.nih.gov/pubmed/30081915
http://dx.doi.org/10.1186/s12985-018-1032-5
_version_ 1783345459615498240
author Diarra, Birama
Yonli, Albert Theophane
Ouattara, Abdoul Karim
Zohoncon, Theodora Mahoukèdè
Traore, Lassina
Nadembega, Christelle
Obiri-Yeboah, Dorcas
Yara, Justine
Pietra, Virginio
Ouedraogo, Paul
Bougouma, Alain
Sanogo, Rokia
Simpore, Jacques
author_facet Diarra, Birama
Yonli, Albert Theophane
Ouattara, Abdoul Karim
Zohoncon, Theodora Mahoukèdè
Traore, Lassina
Nadembega, Christelle
Obiri-Yeboah, Dorcas
Yara, Justine
Pietra, Virginio
Ouedraogo, Paul
Bougouma, Alain
Sanogo, Rokia
Simpore, Jacques
author_sort Diarra, Birama
collection PubMed
description BACKGROUND: Burkina Faso is a high endemicity country for HBV infection. However, there are few data on vaccine coverage against HBV. The aim of this study was to contribute to the improvement of HBV vaccine coverage in Ouagadougou through HBV screening. METHODS: Awareness campaigns and voluntary hepatitis B screening were organized in the twelve districts of Ouagadougou by the “SOS Hepatitis Burkina” association. A rapid HBsAg detection test (Abon Biopharma Guangzhou, Co., Ltd. Chine) was performed on 2216 individuals, who voluntarily answered a series of questions. Vaccination against hepatitis B was proposed to HBV negative participants. RESULTS: In a sample of 2216 participants, aged 1 to 78 years (mean age 29.7 ± 14.7 years); a prevalence of 10.4% (230/2216) of HBsAg was obtained. This prevalence was high in the age groups 31 to 40 years (14.5%) and 41 to 50 years (15.0%). The prevalence of HBV was higher in the sixth district (14.3%) of Ouagadougou. At the end of the screening, 1202/1986 HBV negative participants were vaccinated, resulting in a vaccination rate of 60.5%. Vaccination coverage ranged from 44.5 to 73.7% all twelve districts. CONCLUSIONS: This study still reports a high prevalence of HBV infection among young people with a peak in the sixth district of Ouagadougou. The study achieved high vaccination coverage in all age groups and districts of Ouagadougou. TRIAL REGISTRATION: The present study has been approved by the Ethics Committee for Health Research of Burkina Faso. CERS201501006 Registered 14 January 2015.
format Online
Article
Text
id pubmed-6080359
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60803592018-08-09 World hepatitis day in Burkina Faso, 2017: seroprevalence and vaccination against hepatitis B virus to achieve the 2030 elimination goal Diarra, Birama Yonli, Albert Theophane Ouattara, Abdoul Karim Zohoncon, Theodora Mahoukèdè Traore, Lassina Nadembega, Christelle Obiri-Yeboah, Dorcas Yara, Justine Pietra, Virginio Ouedraogo, Paul Bougouma, Alain Sanogo, Rokia Simpore, Jacques Virol J Research BACKGROUND: Burkina Faso is a high endemicity country for HBV infection. However, there are few data on vaccine coverage against HBV. The aim of this study was to contribute to the improvement of HBV vaccine coverage in Ouagadougou through HBV screening. METHODS: Awareness campaigns and voluntary hepatitis B screening were organized in the twelve districts of Ouagadougou by the “SOS Hepatitis Burkina” association. A rapid HBsAg detection test (Abon Biopharma Guangzhou, Co., Ltd. Chine) was performed on 2216 individuals, who voluntarily answered a series of questions. Vaccination against hepatitis B was proposed to HBV negative participants. RESULTS: In a sample of 2216 participants, aged 1 to 78 years (mean age 29.7 ± 14.7 years); a prevalence of 10.4% (230/2216) of HBsAg was obtained. This prevalence was high in the age groups 31 to 40 years (14.5%) and 41 to 50 years (15.0%). The prevalence of HBV was higher in the sixth district (14.3%) of Ouagadougou. At the end of the screening, 1202/1986 HBV negative participants were vaccinated, resulting in a vaccination rate of 60.5%. Vaccination coverage ranged from 44.5 to 73.7% all twelve districts. CONCLUSIONS: This study still reports a high prevalence of HBV infection among young people with a peak in the sixth district of Ouagadougou. The study achieved high vaccination coverage in all age groups and districts of Ouagadougou. TRIAL REGISTRATION: The present study has been approved by the Ethics Committee for Health Research of Burkina Faso. CERS201501006 Registered 14 January 2015. BioMed Central 2018-08-06 /pmc/articles/PMC6080359/ /pubmed/30081915 http://dx.doi.org/10.1186/s12985-018-1032-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Diarra, Birama
Yonli, Albert Theophane
Ouattara, Abdoul Karim
Zohoncon, Theodora Mahoukèdè
Traore, Lassina
Nadembega, Christelle
Obiri-Yeboah, Dorcas
Yara, Justine
Pietra, Virginio
Ouedraogo, Paul
Bougouma, Alain
Sanogo, Rokia
Simpore, Jacques
World hepatitis day in Burkina Faso, 2017: seroprevalence and vaccination against hepatitis B virus to achieve the 2030 elimination goal
title World hepatitis day in Burkina Faso, 2017: seroprevalence and vaccination against hepatitis B virus to achieve the 2030 elimination goal
title_full World hepatitis day in Burkina Faso, 2017: seroprevalence and vaccination against hepatitis B virus to achieve the 2030 elimination goal
title_fullStr World hepatitis day in Burkina Faso, 2017: seroprevalence and vaccination against hepatitis B virus to achieve the 2030 elimination goal
title_full_unstemmed World hepatitis day in Burkina Faso, 2017: seroprevalence and vaccination against hepatitis B virus to achieve the 2030 elimination goal
title_short World hepatitis day in Burkina Faso, 2017: seroprevalence and vaccination against hepatitis B virus to achieve the 2030 elimination goal
title_sort world hepatitis day in burkina faso, 2017: seroprevalence and vaccination against hepatitis b virus to achieve the 2030 elimination goal
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080359/
https://www.ncbi.nlm.nih.gov/pubmed/30081915
http://dx.doi.org/10.1186/s12985-018-1032-5
work_keys_str_mv AT diarrabirama worldhepatitisdayinburkinafaso2017seroprevalenceandvaccinationagainsthepatitisbvirustoachievethe2030eliminationgoal
AT yonlialberttheophane worldhepatitisdayinburkinafaso2017seroprevalenceandvaccinationagainsthepatitisbvirustoachievethe2030eliminationgoal
AT ouattaraabdoulkarim worldhepatitisdayinburkinafaso2017seroprevalenceandvaccinationagainsthepatitisbvirustoachievethe2030eliminationgoal
AT zohoncontheodoramahoukede worldhepatitisdayinburkinafaso2017seroprevalenceandvaccinationagainsthepatitisbvirustoachievethe2030eliminationgoal
AT traorelassina worldhepatitisdayinburkinafaso2017seroprevalenceandvaccinationagainsthepatitisbvirustoachievethe2030eliminationgoal
AT nadembegachristelle worldhepatitisdayinburkinafaso2017seroprevalenceandvaccinationagainsthepatitisbvirustoachievethe2030eliminationgoal
AT obiriyeboahdorcas worldhepatitisdayinburkinafaso2017seroprevalenceandvaccinationagainsthepatitisbvirustoachievethe2030eliminationgoal
AT yarajustine worldhepatitisdayinburkinafaso2017seroprevalenceandvaccinationagainsthepatitisbvirustoachievethe2030eliminationgoal
AT pietravirginio worldhepatitisdayinburkinafaso2017seroprevalenceandvaccinationagainsthepatitisbvirustoachievethe2030eliminationgoal
AT ouedraogopaul worldhepatitisdayinburkinafaso2017seroprevalenceandvaccinationagainsthepatitisbvirustoachievethe2030eliminationgoal
AT bougoumaalain worldhepatitisdayinburkinafaso2017seroprevalenceandvaccinationagainsthepatitisbvirustoachievethe2030eliminationgoal
AT sanogorokia worldhepatitisdayinburkinafaso2017seroprevalenceandvaccinationagainsthepatitisbvirustoachievethe2030eliminationgoal
AT simporejacques worldhepatitisdayinburkinafaso2017seroprevalenceandvaccinationagainsthepatitisbvirustoachievethe2030eliminationgoal